Jefferies Adjusts Astellas Pharma's Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy
Jefferies Adjusts Astellas Pharma's Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy
Taysha Downgraded at Jefferies Citing Uncertain Outlook for Lead Asset
Taysha Gene Therapies Downgraded to Neutral at Goldman Sachs on Measured Outlook
No Data